Đang chuẩn bị liên kết để tải về tài liệu:
BET Bromodomain inhibition promotes Derepression of TXNIP and activation of ASK1- MAPK pathway in acute myeloid leukemia

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG Tải xuống

Targeted therapy has always been the focus in developing therapeutic approaches in cancer, especially in the treatment of acute myeloid leukemia (AML). A new small molecular inhibitor, JQ1, targeting BRD4, which recognizes the acetylated lysine residues, has been shown to induce cell cycle arrest in different cancers by inhibiting MYC oncogene. | BET Bromodomain inhibition promotes Derepression of TXNIP and activation of ASK1- MAPK pathway in acute myeloid leukemia